title: Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.
abstract: Integration of the DNA copy of the HIV-1 genome into a host chromosome is required for viral replication and is thus an important target for antiviral therapy. The HIV-encoded enzyme integrase (IN) catalyzes two essential steps: 3' processing of the viral DNA ends, followed by the strand transfer reaction, which inserts the viral DNA into host DNA. Raltegravir binds to IN and blocks the integration of the viral DNA. Using the Rous sarcoma virus-derived vector RCAS, we previously showed that mutations that cause one viral DNA end to be defective for IN-mediated integration led to abnormal integrations in which the provirus had one normal and one aberrant end, accompanied by rearrangements in the host genome. On the basis of these results, we expected that suboptimal concentrations of IN inhibitors, which could block one of the ends of viral integration, would lead to similar aberrant integrations. In contrast to the proviruses from untreated cells, which were all normal, ∼10-15% of the proviruses isolated after treatment with a suboptimal dose of raltegravir were aberrant. The aberrant integrations were similar to those seen in the RCAS experiments. Most of the aberrant proviruses had one normal end and one aberrant end and were accompanied by significant rearrangements in the host genome, including duplications, inversions, deletions and, occasionally, acquisition of sequences from other chromosomes. The rearrangements of the host DNA raise concerns that these aberrant integrations might have unintended consequences in HIV-1-infected patients who are not consistent in following a raltegravir-containing treatment regimen.
authors: HIV Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
authors: Janani
authors: J
authors: Varadarajan
authors: Mary Jane
authors: MJ
authors: McWilliams
authors: Stephen H
authors: SH
authors: Hughes
mesh_terms: D045744:Cell Line, Tumor; D004279:DNA, Viral / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology; D057809:HEK293 Cells; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics / Q000821:virology; D019427:HIV Integrase / Q000235:genetics / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008957:Models, Genetic; D008958:Models, Molecular; D015394:Molecular Structure; D009690:Nucleic Acid Conformation; D011485:Protein Binding; D011533:Proviruses / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D011760:Pyrrolidinones / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D000068898:Raltegravir Potassium; D016662:Virus Integration / Q000187:drug effects* / Q000235:genetics; D014779:Virus Replication / Q000187:drug effects* / Q000235:genetics
chemical_list: D004279:DNA, Viral; D004791:Enzyme Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D019427:HIV Integrase
keywords: chromosomal rearrangements; integrase inhibitors; strand transfer inhibitor
references: J Natl Cancer Inst. 2011 May 4;103(9):753-62
references: 21483021
references: J Virol. 2006 Jan;80(1):451-9
references: 16352569
references: Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10380-5
references: 15240889
references: Clin Infect Dis. 2009 Apr 1;48(7):931-9
references: 19231980
references: Clin Infect Dis. 2012 Nov;55(9):1228-35
references: 22776851
references: Retrovirology. 2008 Dec 17;5:114
references: 19091057
references: J Comput Chem. 2012 Feb 15;33(5):527-36
references: 22144113
references: Antimicrob Agents Chemother. 2011 Sep;55(9):4090-5
references: 21746959
references: Nature. 2010 Mar 11;464(7286):232-6
references: 20118915
references: J Virol. 2010 Oct;84(19):9864-78
references: 20660205
references: J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20
references: 12843741
references: Science. 1994 Dec 16;266(5192):1865-9
references: 7997879
references: Annu Rev Pharmacol Toxicol. 2009;49:377-94
references: 18928385
references: Blood. 2009 Feb 5;113(6):1213-24
references: 18955561
references: Braz J Infect Dis. 2010 Sep-Oct;14(5):513-8
references: 21221483
references: Science. 2000 Jan 28;287(5453):646-50
references: 10649997
references: Proc Natl Acad Sci U S A. 1989 Apr;86(8):2525-9
references: 2539592
references: Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20057-62
references: 21030679
references: Curr Opin Struct Biol. 2011 Apr;21(2):249-56
references: 21277766
references: J Med Chem. 2008 Sep 25;51(18):5843-55
references: 18763751
references: Virology. 2000 Dec 5;278(1):133-6
references: 11112489
references: Virology. 2012 May 25;427(1):44-50
references: 22374236
references: J Virol. 1998 Jun;72(6):4678-85
references: 9573231
references: EMBO J. 2006 Mar 22;25(6):1295-304
references: 16482214
references: Ann N Y Acad Sci. 2011 Mar;1222:83-9
references: 21434946
references: J Virol. 2008 Jan;82(2):719-27
references: 17989171
references: J Clin Oncol. 2008 Oct 10;26(29):4834-42
references: 18591544
references: Eur J Cancer. 2001 Jul;37(10):1217-26
references: 11423254
references: Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161
references: 22474613